Results 171 to 180 of about 82,658 (284)

Temporal Characteristics and Management of Prolonged Sinus Pause Following Atrial Fibrillation Termination After Catheter Ablation—A Preliminary Study

Annals of Noninvasive Electrocardiology, Volume 31, Issue 2, March 2026.
Twelve of the 1330 patients who underwent AF catheter ablation showed PSP ≥ 3 s after AF termination post ablation. The temporal characteristics of PSP were described. Nine of the 12 patients had no need for permanent pacing. We concluded that a ‘watch‐and‐wait’ strategy could be adopted in these patients.
Yi Guo, Cheng Cai, Hongwu Chen, Kai Gu, Weizhu Ju, Gang Yang, Jiaojiao Shi, Zidun Wang, Hailei Liu, Xiaohong Jiang, Chang Cui, Mingfang Li, Minglong Chen   +12 more
wiley   +1 more source

Phenotypic Analysis of P-Wave Morphology as a Key Determinant of Late Recurrence Post-Ablation in Paroxysmal Atrial Fibrillation. [PDF]

J Arrhythm
Yano M, Egami Y, Kobayashi N, Sugino A, Abe M, Ohsuga M, Nohara H, Kawanami S, Ukita K, Kawamura A, Yasumoto K, Okamoto N, Matsunaga-Lee Y, Nishino M.   +13 more
europepmc   +1 more source

Marked QTc Interval Prolongation Associated With Dronedarone in Paroxysmal Atrial Fibrillation and No Structural Disease. [PDF]

Cureus
Hernandez Mejia S, Fahed J, Isber R, Isber N.   +3 more
europepmc   +1 more source

Impact of small left ventricle on paroxysmal atrial fibrillation ablation. [PDF]

Medicine (Baltimore)
Pang Z, Wang T, Jia Y.
europepmc   +1 more source

Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion‐dependent aplastic anaemia: West Japan Hematology Study Group (W‐JHS) AA02 trial

British Journal of Haematology, Volume 208, Issue 3, Page 1084-1092, March 2026.
Summary The efficacy of a triple combination of rabbit anti‐human thymocyte immunoglobulin (rATG), ciclosporin and eltrombopag (EPAG) was prospectively evaluated in patients with severe or transfusion‐dependent non‐severe aplastic anaemia (SAA) across 29 institutions in Japan. Sixty patients were enrolled, of whom 48 had SAA. The primary end‐point, the
Fumi Nakamura, Ken Ishiyama, Ritsuro Suzuki, Hiroyuki Maruyama, Yasushi Onishi, Kensuke Usuki, Hideo Koh, Katsuto Takenaka, Ryunosuke Saiki, Seishi Ogawa, Kana Matsumoto, Takuto Takahashi, Kazuyoshi Hosomichi, Yoshitaka Zaimoku, Kenichi Yoshimura, Itaru Matsumura, Koichi Akashi, Shinji Nakao   +17 more
wiley   +1 more source

Chylopericardium as a late-onset complication of cryoballoon ablation of paroxysmal atrial fibrillation. [PDF]

HeartRhythm Case Rep
Marjamaa A, Karvonen J, Räsänen J, Suominen S, Aro A, Raatikainen P.   +5 more
europepmc   +1 more source

QT Myopia and Cardiac Safety: Expanding the Aperture of Arrhythmia Assessment in Early Phase Drug Development

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Regulatory agencies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, and the Japanese Pharmaceutical and Medical Device Agency (PMDA) provide scientific and public health guidance with cardiac safety being paramount in drug development of new investigational products (IP).
Robert M. Lester, Katherine Clark, Sabina Paglialunga   +2 more
wiley   +1 more source

The diagnostic value of left atrial stiffness for heart failure with preserved ejection fraction in patients with paroxysmal atrial fibrillation. [PDF]

Echo Res Pract
Lai J, Qin X, Zhang D, Wang J, Yu J, Sun K, Yang D, Fan J, Zhang L, Cheng Z, Cheng K, Gao P, Deng H, Fang L, Chen T, Fang Q, Liu Y.   +16 more
europepmc   +1 more source

Evaluation of predictors indicating paroxysmal atrial fibrillation in patients with acute ischemic strokes: the Find-AF_RANDOMISED trial. [PDF]

Neurol Res Pract
Weber-Krüger M, Zapf A, Protsenko E, Liman J, Hamann GF, Kermer P, Wasser K, Uphaus T, Gröschel S, Gröschel K, Wachter R.   +10 more
europepmc   +1 more source

Paroxysmal atrial fibrillation: treatment choice

Кардиоваскулярная терапия и профилактика, 2007
Characteristics and classification of various paroxysmal atrial fibrillation (AF) forms are presented. Main indications for sinus rhythm restoration are listed, together with characteristics of principal medications used for AF management. Antiarrhythmic choice issue is discussed, with emphasis on individual approaches in choosing treat ment tactics.
openaire   +1 more source